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Summary 
T cell surface receptors CD28 and CTLA-4 are homologous members of the immunoglobulin 
superfamily (IgSF), each comprising a single V-like extracellular  domain. CD28 and CTLA-4 
bind to the B7-1 and B7-2 counter-receptors on antigen presenting cells (APCs), thereby triggering 
a costimulatory pathway important for optimal T cell activation in vitro and in vivo. Soluble 
forms of CD28 and CTLA-4 in which the V-like extracellular domains were fused to Ig constant 
domains (CD28Ig and CTLA4Ig), have been used to study their interactions with B7-1 and 
B7-2, with CTLA4Ig binding B7-1 more strongly than CD28Ig (~20-fold higher avidity). We 
have now, by site-specific and homologue mutagenesis, identified regions in CTLA4Ig important 
for strong binding to B7-1. A hexapeptide motif (MYPPPY) in the complementarity determining 
region 3 (CDR3)-like region is fully conserved in all CD28 and CTLA-4 family members. Alanine 
scanning mutagenesis through the motif in CTLA4Ig and at selected residues in CD28Ig reduced 
or abolished binding to B7-1. Chimeric molecules HS4, HS4-A, and HS4-B were constructed 
in which CDR3-like regions of CTLA-4, COOH-terminally extended to include nonconserved 
residues, were grafted onto CD28Ig. These homologue mutants showed stronger binding to 
B7-1 than did CD28Ig. Grafting of the CDRl-like region of CTLA-4, which is not conserved 
in CD28 and is predicted to be spatially adjacent to CDR3, into HS4 and HS4-A, resulted in 
chimeric molecules (HS7 and HSS) which bound B7-1 even better. Inclusion of the CDR2-1ike 
domain of CTLA-4 into HS7 and HS8 did not further increase binding. Thus, the MYPPPY 
motifs of CTLA4Ig and CD28Ig are important for their binding to B7-1,  but the increased 
strength of this binding by CTLA4Ig is mediated by nonconserved residues in the CDR1- and 
CDR3-analogous regions. 
F 
Lor T cells to respond to an antigenic stimulus, multiple 
activation signals are required from the APC (1, 2). An 
antigen-specific  signal occurs when the TCR binds to anti- 
genic peptides presented by MHC molecules. An important 
nonspecific costimulatory signal is delivered to the T cell when 
B7-related receptors on APCs bind to CD28 and/or CTLA-4. 
There are at least two homologous B7 family members found 
on APCs, B7-1  (also called B7 or CD80) and B7-2,  both 
of which can deliver costimulatory signals to T cells via CD28 
and/or CTLA-4  (3-7).  Costimulation through CD28  or 
CTLA-4 is essential for T cell activation since a soluble Ig 
fusion protein of CTLA-4 (CTLA4Ig) blocks T cell-depen- 
dent immune responses in vitro and in vivo (5, 8, 9). Failure 
to deliver this second signal may lead to clonal inactivation 
or T  cell anergy (10-12). 
CD28 and CTLA-4 both contain a single Ig V-like ex- 
tracellular  ligand binding domain which share  •25%  se- 
quence homology (13-15). The B7 ligands are also members 
of the Ig superfamily (IgSF) 1 but have, in contrast to CD28 
and CTLA-4, two Ig domains in their extraceUular region, 
an NH2-terminal V-like domain and a C-like domain (3, 6, 
7). CTLA4Ig binds to B7-1 with "~20 fold higher avidity 
than a corresponding Ig fusion of CD28 (5, 16) but the mo- 
lecular details of how CD28 and CTLA-4 interact with B7- 
1/B7-2 are not known. In particular,  it is not known what 
determines the different binding a~nities of these receptors 
for their counter-receptors. Using Ig fusion proteins of CTLA-4 
and CD28, we have analyzed regions of these molecules that 
are critical for their interaction with B7-1. The results of site- 
specific and homologue scanning mutagenesis experiments 
combined with an approximate three-dimensional model of 
the CTLA-4 extracellular domain suggest an important role 
1 Abbreviations used in this paper: CHO, Chinese hamster ovary; HKP, 
horseradish peroxidase; IgSF, Ig superfamily; TMB, tetramethylbenzidine. 
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CTLA-4 for the binding to B7-1. 
Materials  and M.ethods 
Cell Culture.  Stably  transfected B7-1  + Chinese hamster ovary 
(CHO) ceils were described previously (16). Cells were maintained 
in DMEM supplemented with  10%  fetal bovine serum (FBS), 
0.2 mM proline, and 1/xM methotrexate. COS cells were grown 
in DMEM supplemented with 10% FBS. 
mAbs and Fusion Proteins.  Anti-CTLA-4 mAbs 7F8 and 10A8 
(17), and anti-CD28 mAb 9.3 (18) have been previously described. 
CD28Ig was prepared in transiently transfected COS cells (16), 
whereas CTLA4Ig was prepared in stably transfected CHO cells 
(8). B7-1mlg fusion protein was prepared by transfecting COS cells 
with plasmid eDNA encoding the extracellular domain of human 
B7-1 genetically fused to eDNA encoding a mouse IgG2a Fc re- 
gion (Brady, W. and P. S. Linsley,  unpublished observations). COS 
cell conditioned media was used as a source for Ig fusion proteins. 
CTLA4Ig and CD28Ig Site-directed Mutant Expression Plasmids. 
Site-directed mutageuesis was performed on eDNA encoding a 
soluble chimeric form of CTLA-4 (CTLA4Ig)  in which the ex- 
tracellular domain of CTLA-4 was genetically fused to the hinge 
and C regions of a human IgG H chain (5). Using the PCR, ala- 
nine residues were introduced at each position of the conserved 
hexapeptide 99MYPPPY104. PCR forward primers were synthe- 
sized encoding the desired mutation and the naturally occurring 
Sad restriction enzyme site immediately preceding the codon en- 
coding amino acid M99. A single reverse primer corresponding to 
the hinge region of a human IgG1 molecule was also used in the 
PCR reactions where CTLA4Ig eDNA was used as the template. 
The PCR products were digested with Sad and BclI (previously 
engineered into the junction site of eDNA encoding the extracel- 
lular domain of CTLA-4 and the hinge region of the human IgG), 
and in a three-way ligation fused to PCR-amplified human  IgG 
H chain eDNA encoding the hinge and C regions (digested with 
BclI and XbaI),  and SacI/XbaI-cut  CDM8-CTLA-4  plasmid. 
CD28Ig site-directed mutants  were prepared by encoding the 
desired mutation in overlapping  oligonucleotide primers and gener- 
ating the mutants by PCR (19). Using a CD28Ig plasmid as the 
template, two mutants were prepared  encoding the mutations P103A 
and Y104A from the CD28 99MYPPPY104 hexapeptide. Other 
flanking PCR primers synthesized for these reactions  were designed 
to allow the final PCR products to be digested with HindlII and 
XbaI and ligated into HindlII/XbaI-digested CDMS. 
PCR conditions consisted of 6 min at 94~  followed  by 25 cycles 
of 1 min at 94~  2 min at 55~  and 3 min at 720C. Taq poly- 
merase and reaction conditions were used as suggested  by the vendor 
(Perkin Elmer Cetus, Emeryville, CA). To confirm that the desired 
mutations had been inserted and to verify the absence of secondary 
mutations, each site-directed mutant was sequenced  by the dideoxy 
chain termination/extension reaction with Sequenase  reagents used 
according to the manufacturer's recommendations (United States 
Biochemical  Corp., Cleveland, OH). Plasmids were transfected  into 
COS cells (20) and the conditioned  media was used as a source 
for Ig fusion proteins. 
CTLA 4Ig Homologue  Mutant Extnession Plasmids.  14 homologue 
scan mutant plasmids were designed to introduce CTLA-4 eDNA 
sequences into CD28Ig while, at the same time, deleting the equiva- 
lent region from CD28. Similarly, two mutant plasmids (HS3 and 
HS6) were designed to introduce CD28 sequences  into CTLA4Ig. 
Each eDNA construct was genetically linked to eDNA encoding 
the hinge and C regions of a human IgG1 in order to make soluble 
chimeras. HS1, HS2, HSS, and HS6 were constructed using a two- 
step PCR by initially  amplifying appropriate  regions of  eDNA then, 
using flanking 5' and 3' PCR primers encoding HindlII and BclI 
restriction sites respectively,  fragments whose sequences  overlapped 
were fused together and amplified  (19). PCR products were digested 
with HindlII and BclI and ligated to HindlII/XbaI-cut CDM8 
along with a Bd/XbaI-digested PCR fragment encoding the human 
IgG H chain hinge and C region. HS3 and HS4 hybrids were pre- 
pared by exchanging SacI/XbaI-cut  fragments  of CD28Ig and 
CTLA4Ig.  A SacI restriction  site was present in CTLA4Ig and 
engineered into CD28Ig at the same relative position by mutating 
V98L using overlapping PCR primer-directed mutagenesis (19). 
This substitution did not affect the ability of the mutant CD28Ig 
to bind B7-1 relative to wild-type CD28Ig. HS4-A and HS4-B were 
also constructed by overlapping PCR primer-directed mutagenesis 
using HS4 as a template. PCR products were digested with SacI 
and BclI and ligated into similarly  digested HS4-CDMS. HS7, HS8, 
and HS9 were prepared by replacing a 5' HindlII/HpaI fragment 
of HS4, HS4-A, and HS4-B, respectively,  with the equivalent  eDNA 
fragment similarly  digested from HSS, thus introducing the CDR1- 
like loop of CTLA-4 into those CD28Ig hybrids already containing 
the CTLA-4 CDR3-1ike regions. HSllYHS14  were prepared  by over- 
lapping PCR primer-directed mutageuesis in which  the CD28 
CDR2-like loop of previously prepared homologue mutants  was 
replaced with the homologous loop from CTLA4Ig.  Thus, HS4 
served as a template to make HS10, HS7 to make HS11, HS4-A 
to make HS12, HS8 to make HS13, and CD28Ig to make HS14. 
All mutants were sequenced  by the dideoxy  chain termination/exten- 
sion reaction. Plasmids encoding each of the mutants were trans- 
fected into COS cells and the resulting culture media used as a 
source for soluble Ig fusion proteins. 
Enzyme Ira munoassays.  To quantitate Ig fusion proteins in cul- 
ture media, microtiter  plates (Immulon2;  Dynatech Labs., Inc., 
Chantilly, VA) were coated with 0.5 #g/ml goat anti-human IgG 
(Jackson ImmunoResearch Labs., Inc., West Chester, PA) for 16 h 
at 4~  Wells were blocked for I h with specimen diluent (Genetic 
Systems, Seattle, WA), then washed with PBS containing 0.05% 
Tween 20 (PBS-Tween). COS cell culture media containing fusion 
protein was added and incubated for 1 h at 22~  Known concen- 
trations of CTLA4Ig were also added to separate wells on each 
plate. After washing, horseradish  peroxidase  (HRP)-conjugated goat 
anti-human IgG (Tago, Inc., Burlingame, CA) diluted 1:12,000, 
was added and incubated for I h at 22~  Wells were then washed 
and incubated with 3,Y,5,5' tetrametbylbenzidine (TMB) substrate 
(Genetic Systems) for 15 min before stopping the reaction by the 
addition  of  1  N  H2S04. Absorbance  was  measured  at  dual 
wavelengths of  450 and 630 nm on a mierotiter plate reader (Genetic 
Systems). Concentrations  of mutant fusion proteins were deter- 
mined by comparison with the linear range of a standard curve 
of known concentrations of CTLA4Ig. Triplicate determinations 
were made and replicates differed from the mean by <10%. Ex- 
periments were repeated at least twice. The ability of CTLA4Ig 
point mutants, and CTLA4Ig/CD28Ig homologue mutants to bind 
B7-1 was measured using  stably transfected B7-1  + CHO cells. 
Round bottom, tissue culture-treated,  96-well microtiter  plates 
(Coming Inc., Coming, NY) were seeded with B7-1  § CHO cells 
at 10  ~ cells/well. 2 d later, the confluent cells were fixed in 95% 
ethanol, washed with PBS-Tween,  and mutant fusion proteins added 
and incubated for 1 h at 22~  After washing, HRP-conjugated 
goat anti-human IgG (Tago Inc.) was added followed  by TMB sub- 
strate and absorbances read. Site-directed mutants of  CD28Ig were 
assayed for their ability to bind to recombinant B7-1mlg fusion 
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Wells were blocked, washed with PBS-Tween, and COS call cul- 
ture media added and incubated for 1 h at 22"C. Known concen- 
trations of  CD28Ig were also added to separate  wells on each plate. 
After washing, HRP-conjugated goat anti-human IgG (Tago Inc.) 
was added followed by TMB substrate and absorbances read. 
Iramunotrrecipitation  and Western  Blot  Analysis. CTLA4Ig/CD28Ig 
homologue scan mutant fusion proteins present in culture media 
were adsorbed to protein A-Sepharose by overnight incubation at 
4~  Beads were washed twice with PBS before addition of SDS 
PAGE sample buffer. The eluted proteins were electrophoresed in 
8% SDS polyacrylamide gels and transferred onto nitrocellulose 
membranes. Membranes were blocked for 16 h  with specimen 
diluent (Genetic Systems), washed in PBS-Tween, and incubated 
with HRP-conjugated goat anti-human IgG (Tago Inc.) diluted 
1:10,000. Blots were washed and developed  using the enhanced  che- 
miluminescence  (ECL) Western blotting detection reagents (Amer- 
sham, Arlington Heights, IL) as specified  by the manufacturers. 
CTLA-4 Molecular  Model.  An approximate three-dimensional 
model of the CTLA-4 extracellular domain was generated based 
on the conservation of consensus residues of IgSF V-like domains. 
Using such consensus  residues  as "anchor  points" for sequence  align- 
ments, CTLA-4 residues were assigned to the A, B, C, C', C", D, 
E, F, G strands of  an Ig V fold (21) and the connecting loop regions. 
The CTLA-4 model was built  (Insight  II,  Discover, molecular 
modeling and mechanics programs, respectively,  Biosym Technol- 
ogies, Inc., San Diego, CA, 1993) using the VH chain of HyHEL- 
5 (22) as template structure. Side  chain replacements and loop con- 
formations  were approximated  using conformational  searching  (23). 
Several versions  of  the model with modified  assignments  of  residues 
to/~-strands or loops were tested using three-dimensional profile 
analysis  (24) in order to improve  the overall  alignment  of  the CTLA-4 
extracellular region sequence with an IgSF V fold. 
Results 
Construction and Binding Activity of CTLA4Ig and CD28Ig 
Point Mutants.  A sequence alignment of the extraceUular do- 
main of various homologues of CTLA-4 and CD28 is shown 
in Fig.  1.  Residues referred to in this study are numbered 
according to the alignment in Fig. 1. Conserved residues are 
scattered throughout the extraceUular domains of these pro- 
teins. A number of these are consensus residues of the IgSF 
rather than residues unique to the CTLA-4/CD28 family (25). 
The most notable conservation of amino acids that are not 
IgSF consensus residues is the hexapeptide MYPPPY sequence 
motif located in the CDR3-1ike loop of both CTLA-4 and 
CD28.  This sequence  conservation suggests a role for this 
region in the interaction with B7-related molecules. To test 
this hypothesis, we performed site-directed  mutagenesis on 
soluble Ig fusions of CTLA-4 and CD28 and assessed the 
ability of these soluble mutants to bind B7-1. Alanine-scanning 
mutations were  introduced into  the  MYPPPY  region  of 
CTLA4Ig using PCR oligonudeotide primer-directed muta- 
genesis.  Similarly,  two alanine mutations were introduced 
into the CD28Ig MYPPPY motif. The concentrations of mu- 
tant Ig fusion proteins in serum-free COS cell culture media 
were determined by an Ig quantitation assay. The structural 
integrity of mutant fusion proteins was examined by assessing 
their ability to bind mAbs specific to CTLA-4 (7F8 and 10A8) 
(17) or CD28 (9.3) (18) in an indirect immunoassay, mAbs 
7F8 and 10A8 bound to each of the CTLA4Ig mutants to 
a level similar to CTLA4Ig, indicating that the epitope(s) 
for these mAbs were unaffected by the mutations, mAb 9.3 
failed to bind to the CD28Ig mutant P103A but bound weakly 
to Y104A,  suggesting that the MYPPPY hexapeptide was 
required for the epitope of this mAb. 
The ability of  each CTLA4Ig mutant to bind to B7-1 trans- 
fected CHO cells was determined by an indirect cdl binding 
immunoassay, and the binding of CD28Ig mutants to B7- 
lIg was assessed by an indirect enzyme immunoassay. Muta- 
genesis of each residue of the CTLA4Ig MYPPPY motif to 
Ala had a profound effect on binding to B7-1 (Fig. 2 A  and 
Table 1). Mutants Y100A and Pl02A bound to B7-1 but con- 
siderably less than wild-type CTLA4Ig. In contrast, mutants 
Figure  1.  Sequence alignment 
of  the  extracellular regions of 
CTLA-4/CD28 family members. 
Sequences are  aligned from the 
predicted NH2 terminus  of mature 
human CTLA-4 (15) and num- 
bering is based on this alignment. 
The  predicted CDR-analogous 
regions are shown. Dark and stip- 
pled boxed areas highlight com- 
pletdy  conserved  and conservatively 
substituted residues, respectively. 
Asterisks denote  cysteine  residues. 
These sequence data are available 
from  EMBL/GenBank/DDBJ 
under  the  following accession 
numbers: human CTLA-4 (HC'F- 
LA4), L15006; murine CTLA-4 
(MCTLA4),  X05719;  murine 
CD28  (MCD28), M34563, rat 
CD28  (RCD28), X55288; hu- 
man  CD28 (HCD28), J02988; 
and chicken CD28 (CHCD28), 
X67915. 
2051  Peach et al. A 
1200 
1000 
800 
i  600 
400 
200 
0 
0.0001 
B 
1  4o0 
￿9  CTLA41g 
￿9  vt0oa  /,- 
￿9  PlolA  12oo 
o  P10~.A  // 
1000 
800 ' 
60O 
400 
200 
,  ....  tt,tl  0 
0.0010  0.0100  0.1000  1,0000 
Fusion protein (~glml) 
T 
O.Ol 
CD2mg 
P108A 
Y104A 
O.lO  1  .oo 
Fusion protein (~g~nl) 
Figure 2.  Mutations  in the MYPPPY motif of CTLA4Ig and CD28Ig disrupt binding to B7-1. Site-directed  mutant fusion proteins were produced 
in transiently transfected COS cells, quantitated and tested for their ability to bind to BT-L (A) CTLA4Ig mutants binding to stably transfected, 
ethanol-fixed B7-1  + CHO cells. (B) CD28Ig mutants binding to BT-1Ig immobilized on 96-well  plates. Fusion protein quantitations were determined 
as described in Materials and Methods. Binding data are expressed as the average of duplicate determinations and replicates differed from the mean 
by <10%. The data are representative of at least two experiments. 
M99A, P101A, P103A, and Y104A showed an almost com- 
plete loss of binding. Equivalent results were obtained when 
B7-1 transfected  CHO  cells  were incubated  with  mutant 
CTLA4Ig fusion protein, followed by anti-human Ig-FITC, 
and binding was measured using flow cytometry. CD28Ig 
MYPPPY mutants P103A and Y104A did not bind detect- 
ably to recombinant B7-1mlg immobilized on plastic wells 
(Fig.  2 b).  These results demonstrate a critical role for the 
MYPPPY motif in both CTLA41g and CD28Ig binding to 
B7-1. 
Characterization of  CTLA-4/CD28 Homologue  Mutant Pro- 
tans.  Since the MYPPPY motif is common to both CTLA-4 
and CD28, it cannot account for the observed differences  in 
B7-1 binding to CTLA4Ig and CD28Ig.  To assess the con- 
tribution  of less conserved residues in  CTLA4Ig  to  B7-1 
binding,  a series of homologue scan mutants were prepared 
in which regions of CD28Ig were replaced with the homol- 
ogous regions from CTLA41g. Those hybrid mutants that 
bound more strongly to B7-1 than CD28Ig would indicate 
that  the CTLA-4 region(s) included in the hybrid played a 
specific role in binding.  Regions adjacent to the MYPPPY 
hexapeptide in the CDR3-1ike loop as well as the CDR1- 
and CDR2-1ike loops of CTLA-4,  were tested.  16 hybrid 
cDNA constructs  were prepared  (Fig.  3  and Table 2),  se- 
quenced, transfected into COS cells, and tested for binding 
activity. In an indirect immunoassay, most homologue mu- 
tant proteins bound anti-CD28  mAb 9.3 to a level similar 
to wild-type CD28Ig, indicating that these proteins had main- 
tained structural integrity.  The electrophoretic mobility of 
the hybrid fusion proteins was compared by SDS-PAGE, in- 
cluding Western blotting analysis (Fig. 4). Under nonreducing 
conditions,  the chimeric proteins  migrated  as species with 
relative molecular masses between ~100 and ~150 kD, with 
some proteins having an additional species with relative mo- 
lecular masses between mS0 and 70 kD. Under reducing con- 
ditions, each hybrid fusion protein migrated with a molec- 
ular mass between that of CTLA4Ig (*50 kD) and CD28Ig 
("-,65 kD) (data not shown). These fusion proteins exist as 
mixtures of monomers and disulphide-linked dimers despite 
mutagenesis of the cysteine residues in the hinge region of 
the Fc (5).  Since four of the conserved cysteine residues in 
CTLA-4 and CD28 are likely to form intrachain  disulphide 
bonds (see below, Fig.  6), dimerization  of the fusion pro- 
teins was probably due to cysteine 123 in CTLA-4Ig.  This 
is supported by a recent report (26) of a chicken CD28 homo- 
logue that lacks this cysteine and also does not form disulfide 
linked homodimers  during SDS-PAGE. 
Binding of CTLA4Ig/CD28Ig  Homologue Mutant Proteins 
to B7-1.  Hybrid fusion proteins were tested for their ability 
to bind to B7-1 by the indirect  cell binding  immunoassay 
(Table  1).  Under these conditions,  the binding  of CD28Ig 
to B7-1 CHO cells is not easily detectable at fusion protein 
concentrations <1.0/zg/ml (Fig. 5 A). Hybrids HS1 and HS3 
showed no detectable binding to B7-1 (Table 1) but the hybrids 
HS2 and HS4 bound approximately two and a half orders 
of magnitude better than CD28Ig (Fig. 5 A), * 10% of wild- 
type CTLA4Ig  binding  (Table  1).  Hybrids  HSA4-A  and 
HS4-B did not bind to B7-1 as well as had HS4 but still bound 
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and Homologue Scan Mutants 
Percentage of B7-1 
Mutant  binding activity 
CTLA4Ig  100 
CD28Ig  <0.1 
CTLA4Ig 
M99A  <0.1 
Y100A  3 
P101A  <1 
P102A  3 
P103A  <0.1 
Y104A  <0.1 
HS1  <0.1 
HS2  10 
HS3  <0.1 
HS4  12 
HS4-A  5 
HS4-B  5 
HS5  <0.1 
HS6  10 
HS7  30 
HS8  32 
HS9  5 
HS10  17 
HS11  13 
HS12  5 
HS13  7 
HS14  <0.1 
Specific binding activities  were determined  for each of the indicated  fu- 
sion proteins. The concentration  of a fusion  protein required to give an 
arbitrary A4s0 the same as that found  for CTLA4Ig  was determined  from 
the linear  region of binding curves (see Figs. 2 A and 5 A) and expressed 
as a percentage of specific  binding  activity  of CTLA4Ig. Values represent 
the average of three determinations  from each binding  curve; replicates 
differed from the mean by <20%. Values are representative  of four ex- 
periments. 
greater than 20-fold better than CD28Ig (Fig.  5, A  and B, 
and Table 1). These results demonstrated that the COOH- 
terminally extended region of the CDR3-1ike loop of CTLA-4 
contributed to B7-1  binding. 
To test whether the CDRl-like loop of CTLA-4 was also 
important for B7-1 binding, mutant HS6 was prepared (Fig. 
3).  This hybrid bound B7-1 comparable to HS4 (Fig.  5 a), 
whereas the reciprocal hybrid, HSS, did not bind B7-1 (Table 
1).  Thus, the CDRl-like region of CTLA-4 also played a 
role in B7-1 binding but this region alone could not sustain 
strong binding.  Several hybrids were  constructed to  test 
whether the CDRl-like loop of CTLA-4 could support strong 
binding  associated  with  the  COOH-terminally extended 
CTLA~g 
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Figure  3.  Maps  of CTLA41g/CD28Ig  homologue  scan  mutants.  Con- 
served Ig-like  cysteine  residues (C) at positions 21 and 94 and the mem- 
brane proximal  cysteine  123 are shown, as is the position  of the MYPPPY 
motif. (Open areas) CD28 sequence; (filled areas) CTLA-4  sequence; (st/p- 
pled areas) beginning of IgG Fc (also refer to Table 2). 
CDR3-analogous region of CTLA-4 (Fig. 3). Hybrid HS7 
showed a nearly threefold increase in binding to B7-1 rela- 
tive to HS4,  representing ~30%  of wild-type CTLA4Ig 
binding (Table 1).  Similarly,  hybrid HS8 bound at ~32% 
of wild-type binding (Fig. 5 A and Table 2), ~sixfold better 
than HS4-A. However, grafting the CTLA-4 CDRl-like re- 
gion onto HS4-B to make the hybrid HS9 did not improve 
binding to B7-1 (Table 1). These results demonstrated that 
the CDKl-like loop could augment strong binding to B7-1 
but that residues immediately adjacent to the MYPPPY motif 
were necessary  for CDK1 augmentation. 
Another series of homologue mutants was constructed to 
assess the role of the CDR2-1ike region of CTLA-4 in binding 
to B7-1. Hybrids HS10 and HS12 did not bind B7-1 better 
than HS4 or HS4-A (Fig.  5 b), whereas HS14 did not bind 
measurably to B7-1 (Table 1). The presence of all three CDR- 
like regions of CTLA-4 in hybrids HS11 and HS13 did not 
augment binding to B7-1 (Table 1). Thus, in contrast to the 
CDK1- and CDK3-1ike regions, the CDK2-1ike region does 
not significantly contribute to B7-1  binding. 
CTLA-4 Model.  Fig. 6 shows a schematic representation 
of a molecular model of the extraceUular domain of a CTLA-4 
monomer. Three-dimensional profile analysis indicated that 
the CTLA-4 sequence is, overall, consistent with an Ig V-fold. 
Due to the low sequence identity to any IgSF V-like mole- 
cule with known three-dimensional structure, the "resolu- 
tion" of the model is limited, with some of the structural 
features of the CTLA-4 V-like domain, including the con- 
formations of the CDK-like regions, only approximated.  Res- 
idue Vail17 represents the last amino acid of the CTLA4 Ig- 
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.
 like domain. The conformation of the region between Valll7 
and the membrane-proximal Cys123, which is predicted to 
form the CTLA-4 homodimeric disulfide bond (15), is un- 
certain and schematically represented in extended conforma- 
tion. Although our data show that CTLA-4 is a disulfide- 
linked homodimer (17), we currently have no information 
on how the monomer subunits interact. The CTLA-4 model 
illustrates  the Ig-like disulfide bond between residues Cys21 
and Cys94 and also suggests the presence  of an additional 
(non-Ig) disulfide bond between residues Cys48 and Cys68. 
Two possible  N-linked glycosylation sites in CTLA-4 map 
to solvent-exposed positions of the Ig B-strand framework 
regions. The assignment of CTLA-4 residues to CDR-like 
Figure 4.  SDS-PAGE  analysis  of CTLA4Ig/ 
CD28Ig homologue mutant fusion proteins. 
A]iquots of medium from transfected COS cells 
containing equivalent amounts oflg fusion pro- 
rein (0.4/tg as determined by immunoassay) 
were subjected to immtmoprecipitation, SDS- 
PAGE  under  nonreducing  conditions,  and 
Western  blotting  analysis  as  described  in 
Materials and Methods. (Left) Relative molec- 
ular mass of protein standards. (Upper and/otter 
arrows) Relative mobilities under _rech__,dng  con- 
ditions of CD28Ig and CTLA4Ig monomers, 
respectively. 
regions is shown in Hg. 1. As is generally true for an Ig V-like 
structure, this model shows that the CDRl-like loop is spa- 
tially adjacent to the CDR3-1ike region but that the CDR2- 
analogous loop is more distant. This suggests how residues 
within the CDRl-analogous region modulate the effects of 
the CDR3-analogous region on CTLA-4Ig binding, as shown 
by binding activities  of homologue scan mutants. 
Discussion 
We have demonstrated that the MYPPPY hexapeptide is 
required for binding of CTLA4Ig and CD28Ig to B7-1. This 
hexapeptide  represents  the  most  notable  sequence motif 
A 
1200 
1000 
800 
i  600 
400 
200 
0 
0.0001 
￿9  CTLA41g 
￿9  CD281g  /~ 
￿9  HS2  // 
￿9  HS4  // 
[]  HS6  /  .'￿9 
￿9 
,  ,  ;"?,:ii-  =  .....  -  ....... 
0.0010  0.0100  0.1000  1.0000 
Fusion protein (l~/ml) 
B 
1400 
1200 
1000 
400 
200 
0 
0.001 
￿9  CTLA41g 
￿9  HS4-A 
￿9  1"188 
[]  I'1S12 
........  I  ....  ,  ,,,I 
0.010  0.100 
Fusion protein (iJa/ml) 
Figure  5.  CTLA4Ig/CD281g homologue mutant fusion  proteins demonstrate involvement of CDR-analogous regions in strong binding to B7-1 
CHO cells. Mutants were assayed as described in Fig. 2 A.  (A) Demonstration of the role of the CDK3-analogous region of CTLA4Ig in strong 
binding to B7-1. (B) Demonstration of the role of the CDKl-analogous region of CTLA4Ig in augmenting strong binding to B7-1. Data are expressed 
as the average of duplicate determinations and differed from the mean by <10%.  The data are representative  of at least four experiments. 
2055  Peach et al. Figure 6.  Approximate  molecular model  of monomeric CTLA-4 Ig 
V-like extracelhlar  domain.  The model was constructed  as described in 
Materials and Methods. Highlighte d are the three CDR-analogous regions; 
CDRl-like (green), CDR2-1ike  (red) and COOH-terminally extended 
CDR3-1ike (blue) with the MYPPPY hexapeptide colored in dark blue. 
Cysteine  residues  involved  in disulfide  bonding  are shown (orange  and yellow), 
as are potential  N-linked glycosylation sites (magenta). 
common to CTLA-4 and CD28. Alignment of CTLA-4 and 
CD28 on an Ig-V fold shows that the MYPPPY motif maps 
to the CDR3-1ike loop region in these molecules and is, there- 
fore, predicted to be solvent exposed. The MYPPPY motif 
is distinctly hydrophobic and conformationally constrained 
due to three adjacent proline residues. The rigorous conser- 
vation of this unusual motif  within the CTLA-4/CD28  family 
suggested a functional significance  (15) which we have demon- 
strated by site-directed mutagenesis  analysis. 
Since both CTLA4Ig and CD28Ig have  identical MYPPPY 
motifs, other elements in the extraceUular  domain of  CTLA4Ig 
must account for its stronger avidity in binding to B7-1. We 
have shown by homologue scan mutagenesis that the COOH- 
terminally extended CDR3-analogous region in CTLA-4 is 
important in B7-1 binding.  This region has very little se- 
quence conservation in the CTLA-4/CD28 family. CTLA-4 
contains a number of hydrophobic residues, but the equiva- 
lent region in CD28 features several charged residues and is 
one residue longer (Fig. 1). These differences presumably ac- 
count for the increased binding ability  of soluble hybrids 
bearing the COOH-terminally extended CDR3-1ike region 
of CTLA-4. Due to the method of construction, hybrids in- 
cluding HS4 and HS4-A have  a leucine at position 98 instead 
of valine seen in CD28. In control experiments, this change 
was not responsible for improved binding. 
Another nonconserved  region in  CTLA-4  which con- 
tributes to B7-1 binding is the CDRl-like loop. The sequence 
of the CDRl-like loop  is  highly variable in  the CTLA- 
4/CD28 family (Fig. 1). Homologue scan mutagenesis ex- 
periments showed that the CDRl-like loop of  CTLA4Ig fur- 
ther enhanced the effects of the CDR3-analogous region. In 
contrast, inclusion of the CTLA-4 CDK2-1ike region either 
alone or in combination with the CDR3-1ike region did not 
further improve binding. It will be important to determine 
whether similar CDR-mediated molecular interactions char- 
acterize the binding between CTLA-4/CD28 and the recently 
described B7-2 molecule. B7-1 and B7-2 are only '~25% ho- 
,,mologous but both molecules bind to CTLA4Ig and CD28Ig 
and deliver costimulatory signals to T cells. Binding studies 
utilizing site-directed and homologue scan mutants described 
here should establish whether these functionally similar mol- 
ecules bind similarly to their common receptors. 
Hybrid molecules which included the CTLA-4 CDR3- 
and  CDRl-like  regions  did  not  fully restore  wild-type 
CTLA4Ig binding activity. This suggests that other residues 
in CTLA-4 also contribute to binding. Alternatively, the levels 
of full binding activity may indicate that hybrid molecules 
bear structural perturbations that reduced binding activity, 
though this possibility seems unlikely as mAb 9.3 binding 
to most of  the hybrids was comparable  with wild-type CD28Ig 
(data not shown). 
The indirect  binding assays we have employed in these 
studies show a greater difference in binding activity between 
CTLA4Ig and CD28Ig than was reported for the avidity con- 
stants of the molecules (5). The relationship  of activity in 
indirect binding assays to binding avidity is unclear. Indirect 
binding is measured in a two-step assay  and therefore involves 
more than one equilibrium reaction. Also, the length of time 
during second-step incubations  would tend to favor detec- 
tion of binding reactions having slow off rates. Attempts to 
relate the binding differences reported here to equilibrium 
or kinetic constants  are in progress. 
CD28 exists as a homodimer (13). Our data indicate that 
CTLA-4 is also a homodimer (24), although a recent report 
by Lindsten et al. (27) suggested that CTLA-4 monomers 
rather than homodimers were present on the T cell surface. 
The structural basis for CTLA-4 dimerization is unclear since, 
like CD28, it does not display the conserved B-bulge sequence 
motifs that mediate Fv-like dimerization (28-30).  It is also 
unclear how dimerization affects binding avidity and how 
many binding sites there are per homodimer. Despite repeated 
efforts, we have been unable to express monomeric soluble 
forms of either CTLA-4 or CD28.  In preliminary  experi- 
ments we have expressed a soluble form of the extracellular 
domain of CTLA-4 without the Fc tag. Preparations of this 
molecule, when run on SDS-PAGE, consist largely  of  disulfide- 
linked homodimers and, upon size exclusion column chro- 
matography, migrate with a molecular weight consistent with 
that of a homodimer. This suggests that homodimerization 
is an essential property of CTLA-4. It will be important to 
determine how dimerization of CTLA-4 and CD28 affect 
B7 binding. 
2056  Molecular Interaction between  CTLAo4/CD28  and B7-1 Fusion protein oligomerization might contribute to B7-1 
binding by homologue scan mutants,  but we think  this is 
unlikely. We have observed no direct correlation between the 
degree of fusion protein aggregation and binding ability. We 
previously reported that CTLA4Ig and CD28Ig form higher 
molecular weight aggregates in solution with the lower avidity 
CD28Ig  existing  as larger  species  (5,  16).  Preliminary  ex- 
periments with size exclusion chromatography showed that 
homologue scan mutants also existed as oligomers, but that 
the degree of oligomerization did not correlate with binding 
activity. Equivalent results were obtained when the binding 
assays for the homologue  scan  mutants  HS4,  HS7-8,  and 
HS10-11 were reversed such that purified hybrid fusion pro- 
rein was immobilized and assayed for soluble B7-1mlg binding. 
Immobilization  would be expected to neutralize effects  on 
binding  of hybrid fusion protein  oligomerization.  Finally, 
the specific activity of B7-1 binding was constant for different 
sized oligomers of fusion protein HS7 size fractionated on 
a TSK G3000SW column (TosoHaas Corporation,  Mont- 
gomeryville, PA). Thus, the relative abilities of homologue 
scan mutants to bind B7-1 were not dependent upon protein 
oligomerization. 
The  role of CDK-like  regions  in mediating  the  strong 
binding interaction between CTLA4Ig and B7-1 is in some 
ways analogous to the use of hypervariable regions by anti- 
bodies when binding to antigen.  CDR-analogous loops of 
other IgSF members, or parts of these loops, are also impor- 
tant binding determinants in the CD8-MHC class I interac- 
tion (31, 32) and in the CD4-MHC class II interaction (33, 
34). More recently, a peptide mimetic of the CDR3-1ike loop 
of CD4 was shown to inhibit the pathological role of CD4 + 
helper T cells in experimental allergic encephalomyelitis (35). 
Results presented here suggest that this approach should be 
evaluated as a means of obtaining peptide inhibitors  of the 
molecular interaction between CTLA-4/CD28 family members 
and B7-related molecules. 
We thank Duke Phan for HPLC fractionation of proteins, and Drs. Jeff Ledbetter and Alejandro Aruffo 
for helpful discussions and critical review of the manuscript. 
Address correspondence to Dr.  Robert Peach, Bristol-Myers Squibb Pharmaceutical Research Institute, 
3005 First Avenue, Seattle, WA 98121. 
Received for publication 28 June  1994 and in revised  form 22 August 1994. 
1.  Schwartz, R.H. 1992. Costimulation  of T lymphocytes: the 
role of CD28, CTLA-4, and B7/BB1 in interleukin-2 produc- 
tion and immunotherapy.  Cell. 71:1065. 
2.  Linsley, P.S., and J.A. Ledbetter. 1993. The role of the CD28 
receptor during T cell responses to antigen. Annu. Rev. Im- 
munol. 11:191. 
3.  Freeman,  G.J.,  A.S. Freedman,  J.M.  Segil, G.  Lee, J.F. 
Whitman, and L.M. Nadler. 1989. B7, a new member of the 
Ig superfamily with unique expression on activated and neo- 
plastic B cells. J. Immunol. 143:2714. 
4.  Linsley, P.S., E.A. Clark, andJ.A. Ledbetter. 1990. The T cell 
antigen CD28 mediates adhesion with B cells by interacting 
with the activation antigen, B7/BB1. Proc Natl. Acac~ Sci. USA. 
87:5031. 
5.  Linsley,  P.S., W. Brady, M. Umes, L.S. Grosmaire, N.K. Damle, 
and J.A. Ledbetter. 1991. CTLA-4 is a second receptor for the 
B cell activation antigen  B7. f  Exl~ Ailed. 174:561. 
6.  Freeman, GJ., J.G. Gribben,  V.A. Bonssiotis, J.Y. Ng, V.A. 
Restivo, Jr., L.A. Lombard, G.S. Gray, and L.M. Nadler. 1993. 
Cloning of B7-2: a CTLA-4 counter-receptor  that costimu- 
lates human T cell proliferation. Science (Wash. DC). 262:909. 
7.  Azuma,  M., D. Ito, H. Yagita, K. Okomura, J.H. Phillips, 
L.L. Lanier, and C. Somoza.  1993. B70 antigen  is a second 
ligand for CTLA-4  and CD28. Nature (Lond.). 366:76. 
8.  Linsley, P.S., P.M. Wallace, J. Johnson,  M.G. Gibson, J.L. 
Greene, J.A. Ledbetter, C. Singh, and M.A. Tepper. 1992. Im- 
munosuppression  in vivo by a soluble form of the CTLA-4 
T cell activation molecule. Science (Wash. DC). 257:792. 
9.  Lenschow, D.J., Y. Zeng, J.R. Thistlethwaite, A. Montag, W. 
Brady, M.G. Gibson, P.S. Linsley, and J.A. Bluestone. 1992. 
Long term survival ofxenogeneic pancreatic islet grafts induced 
by CTLA4Ig.  Science (Wash. DC). 257:789. 
10.  Schwartz, R.H. 1990. A cell culture model for T lymphocyte 
clonal anergy. Science (Wash. DC). 248:1349. 
11.  Harding,  F.A., J.G. McArthur, J.A. Gross, D.H. Raulet, and 
J.P. Allison. 1992. CD28-mediated signalling co-stimulates mu- 
rine T cells and prevents induction of anergy in T cell clones. 
Nature (Lond.). 356:607. 
12.  Tan, P., C. Anasetti, J.A. Hansen, J. Melrose, M. Brunvand, 
J. Bradshaw, J.A. Ledbetter, and P.S. Linsley. 1993. Induction 
of alloantigen-specific hyporesponsiveness in human  T lym- 
phocytes by blocking  interaction  of CD28 with its natural 
ligand B7/BB1. J. Exl~ Med. 177:165. 
13.  Aruffo, A., and B. Seed. 1987. Molecular cloning of a CD28 
cDNA by a high effzciency  COS cell expression system. Pro~ 
Natl. Acad. Sci. USA.  84:8573. 
14.  Brunet, J.-F., F. Denizot, M.-E Luciani, M. Roux-Dosseto, 
M. Suzan, M.-G. Mattei, and P. Golstein. 1987. A new member 
of the immunoglobulin  superfamily-CTLA-4. Nature (Lond.). 
328:267. 
15.  Harper, K., C. Balzano, E. Rouvier, M.-G. Mattei, M.-F. Lu- 
ciani, and P. Golstein. 1991. CTLA-4 and CD28 activated lym- 
phocyte molecules are closely related in both mouse and human 
as to sequence message expression, gene structure  and chro- 
2057  Peach et al. mosomal location. J. Immunol.  147:1037. 
16.  Linsley, ES., W. Brady, L. Grosmaire, A. Aruffo, N.K. Damle, 
and J.A. Ledbetter. 1991. Binding of the B cell activation an- 
tigen B7 to CD28 costimulates T cell proliferation and inter- 
leukin 2 mRNA accumulation. J. Exl~ Med.  173:721. 
17.  Linsley, P.S., J.L. Greene, P. Tan, J. Bradshaw, J.A. Ledbetter, 
C. Anasetti, and N.K. Damle. 1992. Coexpression and func- 
tional cooperation of CTLA-4 and CD28 on activated T lym- 
phocytes. J. Ex  F  Med.  176:1595. 
18.  Ledbetter, J.A., P.J. Martin, C.E. Spooner, D. Wofsy, "El'. Tsu, 
P.G. Beatty, and P. Gladstone. 1985. Antibodies to Tp67 and 
Tp44 augment and svstain proliferative responses of activated 
T  cells. J. Immunol.  135:2331. 
19.  Ho, S.N., H.D. Hunt, K.M. Horton, J.K. Pullen, and L.K. 
Pease. 1989.  Site-directed  mutagenesis by overlap  extension 
using the polymerase chain reaction. Gene (Amst).  77:51. 
20.  Aruffo, A., I. Stamenkovic, M. Melnick, C.B. Underhill, and 
B. Seed. 1990. CD44 is the principal cell surface receptor for 
hyaluronate.  Cell. 61:1303. 
21.  Williams,  A.F.,  and A.N. Barklay.  1988. The immunoglob- 
ulin superfamily-domains  for cell surface recognition. Annu. 
Rev. Immunol.  6:381. 
22.  Sheriff,  S.,  E.W.  Silverton, E.A.  Padlan,  G.H.  Cohen,  S.J. 
Smith-Gill,  B.C.  Finzell,  and  D.R.  Davies.  1987.  Three- 
dimensional structure of an antibody-antigen complex. Proc. 
Natl.  Acad. Sci. USA.  84:8075. 
23.  Bruccoleri, K.E., E. Haher, and J. Novotny. 1988. Structure 
of antibody hypervariable loops reproduced by a conformational 
search algorithm. Nature (Lond.). 335:564. 
24.  Luthy, R., J.U. Bowie, and D. Eisenberg.  1992. Assessment 
of protein  models  with  three-dimensional  profiles.  Nature 
(Lond.). 356:83. 
25.  Williams,  A.F. 1987. A year in the life of the immunoglobulin 
superfamily.  Immunol.  Today. 8:298. 
26.  Young, J.R., T.F. Davison, C.A. Tregaskes, M.C. Rennie, and 
O. Vainio. 1994. Monomeric homologue of mammalian CD28 
is expressed  on chicken T  cells. J. Immunol.  152:3848. 
27.  Lindsten, T., K.P. Lee, E.S. Harris, B. Petryniak, N. Craig- 
head, P.J. ~ynolds, D.B. Lombard, G.J. Freeman, L.M. Na- 
dler, G.S. Gray, et al. C.B. Thompson, and C.H. June. 1993. 
Characterization of CTLA-4 structure and expression on human 
T  cells. J. Immunol.  151:3489. 
28.  Leahy, D.J., K. Ax~l, and W. Hendrickson. 1992. Crystal struc- 
ture of a soluble form of the human T cell coreceptor CD8 
at 2.6A  resolution. Cell. 68:1145. 
29.  Chothia, C., J. Novotny, R. Bruccoleri, and M. Karplus. 1985. 
Domain association in immunoglobulin molecules: the packing 
of variable domains. J. Mol. Biol. 186:651. 
30.  Colman, P.M. 1988. Structure of antibody-antigen complexes: 
implications for immune recognition. Adv. Iramunol. 43:99. 
31.  Sanders, S.K., R.O. Fox, and P. Kavathas. 1991. Mutations in 
CD8 that affect interactions with HLA class I and monoclonal 
anti-CD8 antibodies. J. Extx  ivied. 174:371. 
32.  Giblin, P.A., D.J. Leahy, J. Mennone, and P.B. Kavathas. 1994. 
The role of charge and multiple faces of the CD8 alpha/alpha 
homodimer in binding to major histocompatibility complex 
class I molecules: support for a bivalent model. Proc. Natl. Acad. 
Sci.  USA.  91:1716. 
33.  Fleury, S., D. Lamarre, S. Meloche, S.-E. Ryu, C. Cantin, W.A. 
Hendrickson, and R.-P. Sekaly. 1991. Mutational analysis of 
the interaction between CD4 and class II MHC: class II an- 
tigens contact CD4 on a surface opposite the gp120-binding 
site. Cell. 66:1037. 
34.  Moebius, U., L.K. Clayton, S. Abraham, A. Diener, J.Y. Yunis, 
S.C. Harrison, and E.L. Reinherz.  1992.  Human immuno- 
deficiency virus gp120 binding C'C" ridge of CD4 domain 
I is also involved in interaction with class II major histocom- 
patibility complex molecules.  Proc. Natl. Acad. Sci. USA.  89: 
12008. 
35.  Jameson, B.A., J.M. McDonnell, J.C. Marini, and R. Korn- 
gold. 1994. A rationally designed CD4 analogue inhibits ex- 
perimental allergic encephalomyelitis.  Nature (Lond.). 368:744. 
2058  Molecular  Interaction between CTLA-4/CD28 and B7-1 